bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 23, 2024
Abstract
Peptide-based
vaccines
face
limitations
in
immunogenicity
and
stability,
challenges
co-delivering
antigens
adjuvants
effectively.
Virus-based
nanoparticles,
particularly
M13
bacteriophage,
present
a
promising
solution
due
to
their
genetic
modifiability,
intrinsic
adjuvanticity,
efficient
antigen
presentation
capabilities.
Here
we
developed
programmable
phage-based
personalized
cancer
vaccine
enabling
single-step
antigen-adjuvant
assembly.
Specifically,
designed
reprogrammed
(RP)
phage
platform
that
precisely
regulates
Toll-like
receptor
9
activation
by
programming
its
genome
sequence
modulates
density
through
engineering.
Vaccination
studies
with
RP
phages
demonstrated
the
immune
response
could
be
modulated
fine-tuning
adjuvanticity
density,
revealing
an
optimal
dose
for
maximum
efficacy.
The
induced
remarkable
24-fold
increase
neoantigen-specific
CD8
+
T
cells
eradicated
established
MC-38
tumors
when
combined
anti-PD-1
therapy.
These
findings
highlight
phage’s
potential
as
powerful
nanovaccine
vaccines.
Bioengineering,
Journal Year:
2025,
Volume and Issue:
12(5), P. 469 - 469
Published: April 29, 2025
Bacteriophages,
with
their
distinctive
ability
to
selectively
target
host
bacteria,
stand
out
as
a
compelling
tool
in
the
realm
of
drug
and
gene
delivery.
Their
assembly
from
proteins
nucleic
acids,
coupled
modifiable
biologically
unique
properties,
enables
them
serve
efficient
safe
delivery
systems.
Unlike
conventional
nanocarriers,
which
face
limitations
such
non-specific
targeting,
cytotoxicity,
reduced
transfection
efficiency
vivo,
engineered
phages
exhibit
promising
potential
overcome
these
hurdles
improve
outcomes.
This
review
highlights
bacteriophage-based
systems
innovative
for
delivering
therapeutic
agents.
It
explores
strategies
engineering
bacteriophage,
categorizes
principal
types
employed
delivery,
evaluates
applications
disease
therapy.
provides
intriguing
details
use
natural
therapy
diseases
cancer,
bacterial
viral
infections,
veterinary
diseases,
neurological
disorders,
well
phage
display
technology
generating
monoclonal
antibodies
against
various
human
diseases.
Additionally,
CRISPR-Cas9
genetically
is
elucidated.
Furthermore,
it
critical
analysis
challenges
associated
phage-based
systems,
offering
insights
overcoming
obstacles.
By
showcasing
advancements
integration
into
nanotechnology,
this
study
underscores
revolutionize
approaches
inspire
future
innovations
medicine.
Phage
therapy,
the
use
of
bacteriophages
(phages)
to
treat
bacterial
infections,
is
regaining
momentum
as
a
promising
weapon
against
rising
threat
multidrug-resistant
(MDR)
bacteria.
This
comprehensive
review
explores
historical
context,
modern
resurgence
phage
and
phage-facilitated
advancements
in
medical
technological
fields.
It
details
mechanisms
action
applications
phages
treating
MDR
particularly
those
associated
with
biofilms
intracellular
pathogens.
The
further
highlights
innovative
uses
vaccine
development,
cancer
gene
delivery
vectors.
Despite
its
targeted
efficient
approach,
therapy
faces
challenges
related
stability,
immune
response,
regulatory
approval.
By
examining
these
areas
detail,
this
underscores
immense
potential
remaining
hurdles
integrating
phage-based
therapies
into
practices.
Phage
therapy,
the
use
of
bacteriophages
(phages)
to
treat
bacterial
infections,
is
regaining
momentum
as
a
promising
weapon
against
rising
threat
multidrug-resistant
(MDR)
bacteria.
This
comprehensive
review
explores
historical
context,
modern
resurgence
phage
and
phage-facilitated
advancements
in
medical
technological
fields.
It
details
mechanisms
action
applications
phages
treating
MDR
particularly
those
associated
with
biofilms
intracellular
pathogens.
The
further
highlights
innovative
uses
vaccine
development,
cancer
gene
delivery
vectors.
Despite
its
targeted
efficient
approach,
therapy
faces
challenges
related
stability,
immune
response,
regulatory
approval.
By
examining
these
areas
detail,
this
underscores
immense
potential
remaining
hurdles
integrating
phage-based
therapies
into
practices.
Applied and Environmental Microbiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 30, 2024
ABSTRACT
Traditional
antibiotics
have
been
effective
in
many
cases.
However,
the
rise
multidrug-resistant
bacteria
has
diminished
their
therapeutic
efficacy,
signaling
dawn
of
an
era
beyond
antibiotics.
The
challenge
multidrug
resistance
Klebsiella
pneumoniae
is
particularly
critical,
with
increasing
global
mortality
and
rates.
Therefore,
development
alternative
therapies
to
urgently
needed.
Phages,
which
are
natural
predators
bacteria,
inherent
advantages.
comprehensive
information
on
K.
phages
lacking
current
literature.
This
review
aims
analyze
summarize
relevant
studies,
focusing
present
state
phage
therapy
for
infections.
includes
examination
treatment
methodologies,
associated
challenges,
strategies,
new
technologies,
clinical
trial
safety
regulatory
issues,
future
directions
development.
Enhancing
technology
crucial
addressing
evolving
threat
.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Cancer
immunotherapy
holds
significant
promise
for
improving
cancer
treatment
efficacy;
however,
the
low
response
rate
remains
a
considerable
challenge.
To
overcome
this
limitation,
advanced
catalytic
materials
offer
potential
in
augmenting
by
modulating
immunosuppressive
tumor
microenvironment
(TME)
through
precise
biochemical
reactions.
Achieving
optimal
targeting
precision
and
therapeutic
efficacy
necessitates
thorough
understanding
of
properties
underlying
mechanisms
tumor-targeted
materials.
This
review
provides
comprehensive
systematic
overview
recent
advancements
their
critical
role
enhancing
immunotherapy.
It
highlights
types
reactions,
construction
strategies
materials,
fundamental
targeting,
including
passive,
bioactive,
stimuli-responsive,
biomimetic
approaches.
Furthermore,
outlines
various
tumor-specific
strategies,
encompassing
tissue,
cell,
exogenous
TME-responsive,
cellular
TME
strategies.
Finally,
discussion
addresses
challenges
future
perspectives
transitioning
into
clinical
applications,
offering
insights
that
pave
way
next-generation
therapies
provide
substantial
benefits
to
patients
settings.
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 23, 2024
Abstract
Peptide-based
vaccines
face
limitations
in
immunogenicity
and
stability,
challenges
co-delivering
antigens
adjuvants
effectively.
Virus-based
nanoparticles,
particularly
M13
bacteriophage,
present
a
promising
solution
due
to
their
genetic
modifiability,
intrinsic
adjuvanticity,
efficient
antigen
presentation
capabilities.
Here
we
developed
programmable
phage-based
personalized
cancer
vaccine
enabling
single-step
antigen-adjuvant
assembly.
Specifically,
designed
reprogrammed
(RP)
phage
platform
that
precisely
regulates
Toll-like
receptor
9
activation
by
programming
its
genome
sequence
modulates
density
through
engineering.
Vaccination
studies
with
RP
phages
demonstrated
the
immune
response
could
be
modulated
fine-tuning
adjuvanticity
density,
revealing
an
optimal
dose
for
maximum
efficacy.
The
induced
remarkable
24-fold
increase
neoantigen-specific
CD8
+
T
cells
eradicated
established
MC-38
tumors
when
combined
anti-PD-1
therapy.
These
findings
highlight
phage’s
potential
as
powerful
nanovaccine
vaccines.
